GlassScriptPhysician profile
April Murrieta
NPI 1265995237
$1,310.43
in general payments reported to CMS, 2019-2025
23 companies · $682 in 2025
The $682 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $346 · 2024: $158 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,170 · Entertainment: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.73 |
| Entertainment | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $443.91 | 2022-2025 | |
| Glaxosmithkline, LLC. | $108.82 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $106.99 | 2022-2023 | |
| Novo Nordisk INC | $89.62 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $68.36 | 2025 | Spravato |
| Lilly USA, LLC | $60.90 | 2023-2025 | Mounjaro, Zepbound |
| Abiomed | $59.84 | 2024 | Impella |
| Exact Sciences Corporation | $50.89 | 2025 | The Cologuard Plus Collection Kit |
| Inspire Medical Systems, INC. | $42.47 | 2025 | Inspire |
| Springworks Therapeutics, INC. | $33.21 | 2025 | Gomekli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $31.92 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $31.68 | 2025 | Zoryve |
| Dexcom, INC. | $22.46 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $21.82 | 2025 | Xyosted |
| Organon LLC | $17.62 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $16.57 | 2025 | Korlym |
| Medtronic, INC. | $16.27 | 2025 | Vanta Adaptivestim |
| Astrazeneca Pharmaceuticals LP | $15.37 | 2025 | Airsupra |
| Optos, INC. | $15.22 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Sumitomo Pharma America, INC. | $15.02 | 2024 | Gemtesa |
| Shield Therapeutics INC | $14.52 | 2023 | Accrufer |
| Spinal Simplicity, LLC | $13.82 | 2025 | Ha Minuteman G3-R |
| Xeris Pharmaceuticals, INC. | $13.13 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Murrieta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.